Marty joined Spring Bank in 2015 as President, Chief Executive Officer and Director. Previously, he served as CEO of Asmacure Ltée, a venture-backed, clinical-stage biopharmaceutical company which he joined in late 2010. Asmacure Ltée was acquired by a privately-held Canadian life sciences company in July 2015. Prior to Asmacure, Marty was the CEO and a director of Javelin Pharmaceuticals, Inc., a publicly-traded developer of acute care pain products, from March 2008 until July 2010, when he engineered the merger of Javelin with Hospira, Inc. He also served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007, Marty co-founded Pear Tree Pharmaceuticals, Inc., a privately-held developer of women’s healthcare products. He has been involved with or led the commercialization of several important therapies, the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major product regulatory filings. Marty also served as a director on the boards of four private and public biopharmaceutical development companies and currently serves on the board of Asmacure Ltée. Marty holds a BSc in communications from the University of Texas at Austin. He is a trustee of the Barn for the Poorest of the Poor, a non-profit food pantry based in New Jersey.
Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of Origenix Technologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumental in advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. (now Idera Pharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of Topigen Pharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.
Nezam has served as a consultant since 2011 and as our non-executive Chief Medical Officer since 2015. He is a Senior Physician in Hepatology at Beth Israel Deaconess Medical Center in Boston, Massachusetts and Professor of Medicine at Harvard Medical School. Nezam received his MB Bch degreein1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College Dublin and at Boston University School of Medicine. Hisclinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension. His research has been on liverfibrosis and hepatitis B and C. Nezam has served on the advisory boards for the International Coalition to Conquer HCV and the American Liver Foundation, as well as several private pharmaceutical companies. He has served on the Editorial Board of and as a reviewer for multiple journals. He has published more than 200 papers in journals such as New England Journal of Medicine, Gastroenterology, Hepatology, Gut and Journal of Hepatology, as well as 30 book chapters and two books. He is the Senior Editor for the Journal of Viral Hepatitis. Nezam has spoken nationally and internationally on chronic liver disease and received the American Liver Foundation Award for Excellence, a Fulbright Scholarship and the Mitchell Lectureship of the Royal College of Physicians. He is a member of the American Gastroenterology Association, the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Diseases.
Jon joined the company in 2015 with more than 16 years of experience in the life sciences and technology industries ranging from venture-backed start-ups to publicly traded companies. Previously, he served as the Senior Director of Finance of SantarisPharma A/S, which was acquired by F. Hoffman-La Roche Ltd. Prior to Santaris, Jon was the Controller of two international public companies after beginning his career at the Financial Accounting Standards Board as a Postgraduate Technical Assistant and PricewaterhouseCoopers LLP, where he worked in the audit and transaction services practices. In these roles, he has managed finance, accounting, information technology, facilities, business development and other shared service functions.
In addition, Jon has worked on various initial public offerings, secondary offerings, mergers and acquisitions, enterprise resource planning (ERP) implementations and other complex accounting matters. Jon is a certified public accountant in the state of Massachusetts and holds a BBA from the University of Massachusetts Amherst.
Don has been Spring Bank’s Vice President of Operations & Corporate Development since March 2011 and served as a consultant to the Company from 2008 to March 2011. Prior to joining Spring Bank, he was Executive Director of Corporate Development at Idenix Pharmaceuticals, Inc. from 2005 until 2008. Prior to Idenix, Mr. Mitchell held a series of senior marketing positions at Amgen, Inc. Prior to Amgen, Mr. Mitchell was principal consultant at PricewaterhouseCoopers. Mr. Mitchell started his career at Novartis Pharmaceuticals, where he held a series of sales, marketing and business development positions of increasing responsibility. He has a BS from the United States Naval Academy and an MBA from the Darden Graduate School of Business Administration at the University of Virginia. Prior to obtaining his MBA, Mr. Mitchell served as a communications officer and an assistant engineer of the Nuclear Submarines division of the United States Navy.
Kevin brings to Spring Bank over 13 years of experience in the biopharmaceutical industry. Prior to joining Spring Bank, he was senior director, nonclinical and translational research, at Retrophin, Inc., in Cambridge, MA. Before Retrophin, Kevin served in various scientific and research roles of increasing responsibility at Shire Pharmaceuticals and Merck. He has authored more than twelve peer-reviewed publications and contributed to several issued patents and patent applications. Kevin received his B.A. in biology from the University of Richmond, his Ph.D. in biochemistry and molecular biophysics from Virginia Commonwealth University School of Medicine and was a postdoctoral fellow at Massachusetts Institute of Technology.
Garrett Winslow has been Spring Bank’s Vice President, Legal since January 2017. Prior to joining Spring Bank, he was a member in the Corporate and Securities group at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in Boston, Massachusetts, where he advised public and private companies on securities law compliance, corporate governance matters and mergers and acquisitions. Mr. Winslow received his Masters in Taxation from Boston University Law School, J.D. degree from Suffolk University Law School and B.A. degree in Business Administration from the University of Washington.